Healthy Volunteers
Conditions
Keywords
ABP 501, Adalimumab, Humira®
Brief summary
The primary objective of this study is to determine the bioequivalence of ABP 501 (subcutaneous \[SC\] injection) compared to adalimumab (SC injection) as assessed principally by the area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf), and maximum observed serum concentration (Cmax) in Japanese participants.
Interventions
DRUGABP 501
SC injection
DRUGAdalimumab
SC injection
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Participants must sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved ICF before any study-specific procedures are performed. 2. Healthy adult male and female Japanese participants between 18 and 45 years of age, inclusive, at the time of screening. 3. Body mass index (BMI) between 16.0 and 25.0 kg/m2, inclusive, at screening and Day -1. 4. Normal or clinically acceptable physical examination, clinical laboratory test values, vital signs, and electrocardiogram (ECG) (12-lead ECG reporting heart rate and RR, PR, QRS, QT, and QTc intervals), as determined by the investigator, at screening. Physical examination, vital signs, body weight and BMI, clinical laboratory tests, pregnancy test, urinalysis, urine drug screen, and alcohol screen will be repeated on Day -1 (see Table 2-1) and must also be normal or clinically acceptable, as deemed by the investigator. 5. Participants must be current on immunizations per local standards. 6. Participants must be first- or second-generation Japanese: * First-generation Japanese are participants who may be living outside of Japan but were born in Japan to parents of Japanese descent * Second-generation Japanese are participants who were born outside of Japan to first-generation Japanese parents
Exclusion criteria
1. Women of childbearing potential who are unwilling to practice a highly effective method of birth control for the duration of the study and for 5 months following treatment with the investigational product or until the scheduled end-of-study (EOS) (whichever is longer). Acceptable methods of effective birth control include: * Abstinence * Surgical methods: bilateral tubal ligation or vasectomy for the male sexual partner * Hormonal methods * Intrauterine device (IUD) * Two barrier methods (one by each partner) * The male must use a condom (latex or other synthetic material) * The female may select one of the following barrier methods: diaphragm, cervical, or contraceptive sponge 2. Women who are lactating or breastfeeding. 3. Women with a positive pregnancy test. 4. Women planning to become pregnant during the study or within 5 months following treatment with investigational product. 5. History or evidence of a clinically significant disorder (including psychiatric), condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. 6. History or evidence of any bacterial, viral, parasitic, or systemic fungal infections within the past 30 days prior to investigational product administration (eg, upper respiratory tract infection, viral syndrome, flu-like symptoms). Exception: a simple, short-duration common cold within the past 14 days prior to investigational product administration. 7. A recent infection (within 6 months of randomization) requiring inpatient hospitalization or intravenous antibiotics. 8. Known positive tuberculin skin test or exposure to an individual with tuberculosis (TB) or positive QuantiFERON® test or local equivalent (eg, T-Spot®) consistent with previous exposure to TB prior to or during screening (if not treated with appropriate chemoprophylaxis). 9. Tuberculosis or fungal infection seen on available chest x-ray taken within 6 months of screening or at screening. 10. History of malignancy of any type, other than surgically excised nonmelanomatous skin cancers, within 5 years prior to randomization. 11. Positive test for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at screening. 12. Positive screen for alcohol and/or potential drugs of abuse at screening or prior to randomization. 13. Receiving or has received any investigational drug (or is currently using an investigational device) within 30 days or 5 half-lives (whichever is longer), prior to receiving investigational product. 14. Use of any over-the-counter (OTC) or prescription medications within the 14 days or 5 half-lives (whichever is longer), prior to receiving investigational product. Acetaminophen (up to 2 g per day and not more than 4 g per week) for analgesia will be allowed. Hormonal contraceptives are allowed. 15. All herbal medicines (eg, St. John's wort) and supplements consumed by the participant within the 30 days prior to receiving investigational product, and continuing use if applicable, will be reviewed by the investigator and the ICON medical monitor. Written documentation of this review and Amgen acknowledgment of the decision made with respect to eligibility is required for participant participation. 16. Donated blood (including blood products) or experienced loss of blood ≥ 500 mL within 2 months of screening. 17. Received live vaccines ≤ 3 months prior to investigational product administration or are scheduled to receive a live vaccine within 3 months following treatment with investigational product. 18. Known or suspected sensitivity to products derived from mammalian cell lines. 19. Known allergy to natural rubber (latex). 20. Previously received adalimumab or a biosimilar of adalimumab. 21. History of alcohol and/or substance abuse within the last 12 months from screening. 22. Participants who use \> 10 cigarettes per day within the last 3 months or not able to abide by the smoking policy of the clinical pharmacology unit (CPU). 23. Inability or unwillingness to reside at the CPU for 2 consecutive days or inability to be available for follow-up assessments or protocol-required procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCinf of ABP 501 | Day 1 to Day 63 |
| Cmax of ABP 501 | Day 1 to Day 63 |
| AUCinf of Adalimumab | Day 1 to Day 63 |
| Cmax of Adalimumab | Day 1 to Day 63 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time at Which the Maximum Observed Serum Concentration is Observed (Tmax) of ABP 501 | Day 1 to Day 63 | — |
| Tmax of Adalimumab | Day 1 to Day 63 | — |
| Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Day 1 to Day 63 | Any clinically significant changes in vital signs or clinical laboratory test results after the dose of treatment will be recorded as TEAEs. |
| AUClast of Adalimumab | Day 1 to Day 63 | — |
| Area Under the Serum Concentration-time Curve from Time 0 to the Last Quantifiable Concentration (AUClast) of ABP 501 | Day 1 to Day 63 | — |
| Number of Participants With Anti-drug Antibodies (ADA) | Day 1 to Day 63 | — |
| Terminal Phase Elimination Half-life (t1/2) of ABP 501 | Day 1 to Day 63 | — |
| t1/2 of Adalimumab | Day 1 to Day 63 | — |
Outcome results
None listed